Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with high morbidity and
mortality worldwide. To date, limited therapeutic achievements targeting cell proliferation …

Pancreatic cancer is a type of common malignant tumors with high occurrence in the world.
Most patients presented in clinic had pancreatic cancer at advanced stages. Furthermore …

Pancreatic cancer is a malignant disease with high mortality and poor prognosis due to lack
of early diagnosis and low treatment efficiency after diagnosis. Although Gemcitabine (GEM) …

Background and Purpose Pancreatic cancer is a solid tumour that is often fatal. Hence, there
is an urgent need to identify new drug targets for this disease. Highly proliferating cancer …

BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer-related death
worldwide. Gemcitabine is the mainstay treatment for advanced disease. However, almost …

The selective MEK1/2 inhibitor pimasertib has shown anti‐tumour activity in a pancreatic
tumour model. This phase I/II, two‐part trial was conducted in patients with metastatic …

Elevated levels of myeloid-derived suppressor cells (MDSCs) induced by tumor-derived
factors are associated with inhibition of immune responses in patients with gastrointestinal …

Phytochemicals such as phenethyl isothiocyanate (PEITC), indole-3-carbinol (I3C),
xanthohumol (XAN), and resveratrol (RES) have been shown to target signaling pathways …

Abstract Background Tumour-associated lymphocytes (TALs) have been linked with good
prognosis in several solid tumours. This study aimed to evaluate the prognostic significance …

Background/Aim: Overexpression of microRNA-21 (miR-21) indicates chemoresistance in
pancreatic cancer. We evaluated the change of chemosensitivity to gemcitabine through the …